Refine by
Amoydx Therapy Development Equipment & Supplies In Belarus
1 equipment items found
Manufactured by:Amoy Diagnostics Co., Ltd. based inXiamen, CHINA
About 3-7%, 1%, 1%, 0.12%, 0.02%, 0.08% of NSCLC patients have gene fusions in ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3 genes, and approximately 1% of lung adenocarcinoma patients harbor MET exon 14 skipping mutations. Targeted therapies have been developed and approved for use in patients whose tumors have some of the genomic alterations seen in NSCLC. For ...